Diabetes: statins, fibrates, or both?
Cardiovascular disease is the leading cause of mortality in patients with type 2 diabetes. Among the many factors that are involved in the pathogenesis of atherosclerosis in diabetic patients, dyslipidemia plays a major role. It is characterized by an increase in triglycerides, a decrease in high-density lipoprotein cholesterol and normal or mildly elevated low-density lipoprotein cholesterol. The management of patients with diabetic dyslipidemia is difficult because we lack studies specifically designed for diabetic patients. Thus, strategy has to rely on post hoc analyses of landmark intervention trials, which usually include only a small number of diabetic patients, or on rare trials enrolling small cohorts of diabetic patients. When lifestyle changes fail, monotherapy should be tried first with either a statin or a fibrate, depending on triglyceride level. If lipid target values are not reached, a combination therapy can then be initiated, with close follow-up of potential side effects.
Farnier
M
M
Point Medical, Rond-Point de la Nation, Dijon, F-21000, France. mfarnier@ipac.fr
Picard
S
S
D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D002995:Clofibric Acid